Do analysts prefer FEED or AMIX?

Autonomix Medical has a consensus target price of $42.00, suggesting a potential upside of 513.14%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Autonomix Medical is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autonomix Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor FEED or AMIX?

In the previous week, Autonomix Medical had 5 more articles in the media than Nanovibronix. MarketBeat recorded 8 mentions for Autonomix Medical and 3 mentions for Nanovibronix. Autonomix Medical's average media sentiment score of 0.98 beat Nanovibronix's score of 0.96 indicating that Autonomix Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanovibronix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autonomix Medical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FEED or HSCS?

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend NXL or FEED?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate FEED or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts prefer FEMY or FEED?

Femasys currently has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, FEMY or FEED?

Nanovibronix has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 3.02 -$18.63M -$3.53 N/A Nanovibronix $2.55M 1.04 -$18.18M -$8.82 N/A

Is FEMY or FEED more profitable?

Femasys has a net margin of -534.36% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -208.04% -68.88% Nanovibronix -923.20% -54.25% -43.10%

Does the media refer more to FEMY or FEED?

In the previous week, Femasys had 10 more articles in the media than Nanovibronix. MarketBeat recorded 13 mentions for Femasys and 3 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.96 beat Femasys' score of 0.55 indicating that Nanovibronix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanovibronix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nanovibronix (FEED) Competitors

$0.44 +0.06 (+14.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.41 -0.03 (-7.09%)

As of 08/14/2026 07:51 PM Eastern

Compare

FEED vs. AMIX, HSCS, NXL, NVNO, and FEMY

Should you buy Nanovibronix stock or one of its competitors? Nanovibronix's main competitors and comparable companies include Autonomix Medical (AMIX), HeartSciences (HSCS), Nexalin Technology (NXL), enVVeno Medical (NVNO), and Femasys (FEMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nanovibronix compare to Autonomix Medical?

Nanovibronix (NASDAQ:FEED) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Nanovibronix has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.16, suggesting that its share price is 216% less volatile than the broader market.

In the previous week, Autonomix Medical had 5 more articles in the media than Nanovibronix. MarketBeat recorded 8 mentions for Autonomix Medical and 3 mentions for Nanovibronix. Autonomix Medical's average media sentiment score of 0.98 beat Nanovibronix's score of 0.96 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autonomix Medical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autonomix Medical has lower revenue, but higher earnings than Nanovibronix. Autonomix Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.04	-$18.18M	-$8.82	N/A
Autonomix Medical	N/A	N/A	-$16.72M	-$59.03	N/A

Autonomix Medical has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Autonomix Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Autonomix Medical	N/A	-267.73%	-216.75%

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 6.2% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Autonomix Medical has a consensus target price of $42.00, suggesting a potential upside of 513.14%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Autonomix Medical is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nanovibronix beats Autonomix Medical on 8 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to HeartSciences?

Nanovibronix (NASDAQ:FEED) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

HeartSciences has lower revenue, but higher earnings than Nanovibronix. HeartSciences is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.04	-$18.18M	-$8.82	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

HeartSciences has a consensus price target of $8.00, indicating a potential upside of 288.35%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nanovibronix has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

HeartSciences has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
HeartSciences	N/A	-358.60%	-144.82%

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Nanovibronix had 2 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for Nanovibronix and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 1.89 beat Nanovibronix's score of 0.96 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanovibronix	Positive
HeartSciences	Very Positive

Summary

HeartSciences beats Nanovibronix on 9 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, Nexalin Technology and Nexalin Technology both had 3 articles in the media. Nanovibronix's average media sentiment score of 0.96 beat Nexalin Technology's score of -0.04 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
Nanovibronix	Positive

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 12.2% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nexalin Technology has a beta of 4, suggesting that its stock price is 300% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Nanovibronix has a net margin of -923.20% compared to Nexalin Technology's net margin of -4,141.94%. Nanovibronix's return on equity of -54.25% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Nanovibronix	-923.20%	-54.25%	-43.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has higher earnings, but lower revenue than Nanovibronix. Nexalin Technology is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	25.71	-$8.22M	-$0.48	N/A
Nanovibronix	$2.55M	1.04	-$18.18M	-$8.82	N/A

Summary

Nanovibronix beats Nexalin Technology on 7 of the 12 factors compared between the two stocks.

How does Nanovibronix compare to enVVeno Medical?

Nanovibronix (NASDAQ:FEED) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Nanovibronix has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.04	-$18.18M	-$8.82	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

In the previous week, Nanovibronix had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for Nanovibronix and 2 mentions for enVVeno Medical. Nanovibronix's average media sentiment score of 0.96 beat enVVeno Medical's score of 0.43 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Overall Sentiment
Nanovibronix	Positive
enVVeno Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

enVVeno Medical has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
enVVeno Medical	N/A	-62.28%	-56.83%

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nanovibronix has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

Nanovibronix beats enVVeno Medical on 9 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to Femasys?

Femasys (NASDAQ:FEMY) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Femasys has a beta of -2.08, indicating that its stock price is 308% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Femasys currently has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Femasys had 10 more articles in the media than Nanovibronix. MarketBeat recorded 13 mentions for Femasys and 3 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.96 beat Femasys' score of 0.55 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanovibronix has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	3.02	-$18.63M	-$3.53	N/A
Nanovibronix	$2.55M	1.04	-$18.18M	-$8.82	N/A

65.3% of Femasys shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Femasys has a net margin of -534.36% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-208.04%	-68.88%
Nanovibronix	-923.20%	-54.25%	-43.10%

Summary

Femasys and Nanovibronix tied by winning 8 of the 16 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.66M	$5.97B	$7.04B	$13.06B
Dividend Yield	N/A	1.75%	2.56%	10.63%
P/E Ratio	-0.05	26.59	271.26	25.30
Price / Sales	1.04	63.37	603.81	93.78
Price / Cash	N/A	33.83	28.87	38.43
Price / Book	0.01	6.10	11.17	6.52
Net Income	-$18.18M	$149.27M	$3.45B	$346.94M
7 Day Performance	9.28%	2.04%	1.17%	1.08%
1 Month Performance	0.55%	4.02%	2.18%	1.87%
1 Year Performance	N/A	9.03%	62.39%	20.79%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	1.4249 of 5 stars	$0.44 +14.7%	N/A	N/A	$2.66M	$2.55M	N/A	20	Short Interest Decrease Gap Down
AMIX Autonomix Medical	2.9913 of 5 stars	$7.53 -17.4%	$42.00 +457.8%	-71.1%	$8.86M	N/A	N/A	1	Earnings Report Short Interest Increase Gap Down
HSCS HeartSciences	2.8351 of 5 stars	$2.00 -2.4%	$8.00 +300.0%	-39.1%	$7.99M	$4.32K	N/A	10
NXL Nexalin Technology	0.4777 of 5 stars	$0.36 -0.7%	N/A	-55.4%	$7.88M	$275.58K	N/A	3	Earnings Report Short Interest Decrease
NVNO enVVeno Medical	1.5144 of 5 stars	$10.99 -1.3%	N/A	-93.7%	$7.60M	N/A	N/A	30	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. AMIX, HSCS, NXL, NVNO, and FEMY

How does Nanovibronix compare to Autonomix Medical?

Summary

How does Nanovibronix compare to HeartSciences?

Summary

How does Nanovibronix compare to Nexalin Technology?

Summary

How does Nanovibronix compare to enVVeno Medical?

Summary

How does Nanovibronix compare to Femasys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. AMIX, HSCS, NXL, NVNO, and FEMY

How does Nanovibronix compare to Autonomix Medical?

Which has more volatility & risk, FEED or AMIX?

Does the media favor FEED or AMIX?

Which has stronger earnings and valuation, FEED or AMIX?

Is FEED or AMIX more profitable?

Do insiders & institutionals hold more shares of FEED or AMIX?

Do analysts prefer FEED or AMIX?

Summary

How does Nanovibronix compare to HeartSciences?

Which has preferable earnings & valuation, FEED or HSCS?

Do analysts recommend FEED or HSCS?

Which has more volatility & risk, FEED or HSCS?

Is FEED or HSCS more profitable?

Do insiders and institutionals have more ownership in FEED or HSCS?

Does the media refer more to FEED or HSCS?

Summary

How does Nanovibronix compare to Nexalin Technology?

Does the media refer more to NXL or FEED?

Do insiders & institutionals have more ownership in NXL or FEED?

Which has more volatility and risk, NXL or FEED?

Is NXL or FEED more profitable?

Do analysts recommend NXL or FEED?

Which has stronger earnings and valuation, NXL or FEED?

Summary

How does Nanovibronix compare to enVVeno Medical?

Which has stronger valuation and earnings, FEED or NVNO?

Does the media favor FEED or NVNO?

Do analysts rate FEED or NVNO?

Is FEED or NVNO more profitable?

Do institutionals and insiders have more ownership in FEED or NVNO?

Which has more volatility & risk, FEED or NVNO?

Summary

How does Nanovibronix compare to Femasys?

Which has more risk and volatility, FEMY or FEED?

Do analysts prefer FEMY or FEED?

Does the media refer more to FEMY or FEED?

Which has stronger valuation and earnings, FEMY or FEED?

Do insiders & institutionals believe in FEMY or FEED?

Is FEMY or FEED more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools